Home›Stock Screener›Supriya Lifescience

Supriya Lifescience Share Price Today | Stock Price & Supriya Lifescience Share Screener

SUPRIYA Pharmaceuticals & Biotechnology
Live Share Price NSE
₹614.80
▼ -5.85 (-0.94%)
2026-11-18 00:00:00
Live Share Price BSE
₹614.85
▼ -5.55 (-0.89%)
2026-11-18 00:00:00

As of November 18, 2026, the live Supriya Lifescience share price (NSE: SUPRIYA) is ₹614.80 on NSE and ₹614.85 on BSE, down 0.94% from the previous close, with shares trading between ₹610.80 and ₹620.95 in today's trading session, and a 52-week range of ₹553.35–₹1,052.50. Track SUPRIYA market value to gauge the company's total market size. Use the Supriya Lifescience stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Supriya Lifescience opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹890 and net income of ₹177, with EBITDA of ₹273, an operating margin of 29.0% and a profit margin of 19.9%.

Supriya Lifescience Market Cap ₹4,995.16 Cr.
SUPRIYA P/E Ratio (TTM) 28.30
Supriya Lifescience P/B Ratio 4.03
EPS (TTM) ₹25.98
Dividend Yield 0.16%
Debt to Equity -
SUPRIYA 52 Week High ₹1052.50
Supriya Lifescience 52 Week Low ₹553.35
Operating Margin 29.00%
Profit Margin 19.89%
SUPRIYA Revenue (TTM) ₹890.00
EBITDA ₹273.00
Net Income ₹177.00
Total Assets ₹1,357.00
Total Equity ₹1,198.00

Supriya Lifescience Share Price Chart

Track the current stock price of Supriya Lifescience with an interactive chart. Analyse SUPRIYA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Supriya Lifescience stock quote in one place.

The quote of ₹614.80 sits between the 52-week low of ₹553.35 and the 52-week high of ₹1,052.50, and the latest session moved -0.94% from the previous close.

Supriya Lifescience Company Profile - Fundamental Screener

Screen Supriya Lifescience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUPRIYA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE07RO01027.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE07RO01027

Supriya Lifescience Balance Sheet Screener

Screen SUPRIYA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,357, up from ₹1,117 in 2025.

Latest statistics put total assets at ₹1,357 and shareholder funds at ₹1,198.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,357 1,117 921 820 735 446 336 253 245 241
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 689 453 310 262 190 100 99 85 91 89

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 38 33 29 25 19 31 32 24 45 51
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,198 997 815 700 616 269 149 94 55 46
Share Capital 16 16 16 16 16 15 15 15 15 15
Reserves & Surplus 1,182 981 799 683 600 254 134 79 40 31

Supriya Lifescience Income Statement Screener - Profit & Revenue Analysis

Screen Supriya Lifescience income statement and profit fundamentals. Analyze SUPRIYA quarterly results. Supriya Lifescience reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹890 and net profit was ₹177, equal to earnings per unit of ₹22.00, at an operating margin of 29%.

In that period expenses were ₹617, interest cost ₹2 and tax ₹51. The next period listed, 2026-March, shows revenue of ₹839 and net profit of ₹209.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 890 839 706 581 470 538 396 323 286 222 191 172 140
Expenses 617 534 436 397 332 316 218 213 213 191 166 150 121

Operating Costs and Margins

EBITDA 273 306 271 184 138 222 178 110 73 31 25 22 20
Operating Profit % 29.00% 36.00% 37.00% 30.00% 28.00% 40.00% 44.00% 32.00% 23.00% 10.00% 9.00% 12.00% 12.00%
Depreciation 34 28 20 16 12 10 7 6 5 5 5 4 3
Interest 2 2 2 2 3 4 4 7 10 11 12 10 7

Profit and Earnings

Profit Before Tax 238 275 249 166 124 207 167 96 57 15 8 8 10
Tax 51 66 61 47 34 55 44 23 18 6 2 2 2
Net Profit 177 209 188 119 90 152 124 73 39 9 6 6 8
EPS 22.00 25.98 23.35 14.80 11.16 18.86 16.89 10.02 5.39 1.19 3.87 3.89 16.82

Supriya Lifescience Cash Flow Screener - Liquidity Fundamentals

Screen SUPRIYA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹186.

Over the same period, investing activities used ₹176 and financing activities used ₹10.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 186 165 113 64 49 76 117 49 28 27
Investing Activities -176 -152 -174 -124 -60 -47 -25 5 -5 -27

Financing and Net Cash

Financing Activities -10 -8 -22 -10 150 -15 -29 -50 -20 -2
Net Cash Flow 0 4 -83 -70 139 15 62 4 3 -2

Supriya Lifescience Shareholding Pattern Screener

See Supriya Lifescience shareholding pattern with promoter, FII, and DII holdings. Check Supriya Lifescience promoter holding and ownership changes for SUPRIYA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 68.30%, foreign institutions 5.16%, domestic institutions 5.70% and the public 16.22%, spread across 81,161 shareholders.

The shareholder count was 81,161 in 2026-Mar, compared with 82,082 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30%

Institutional Investors

FII Holding 5.16% 6.19% 6.44% 7.19% 6.78% 5.46% 5.20% 5.36%
DII Holding 5.70% 5.30% 5.47% 4.26% 4.86% 5.22% 5.01% 5.30%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 16.22% 15.98% 15.43% 16.40% 16.39% 16.77% 16.66% 17.06%
Other Holding 4.63% 4.23% 4.36% 3.85% 3.67% 4.25% 4.83% 3.98%
Shareholder Count 81,161 82,082 78,561 91,051 91,928 87,912 85,099 87,980

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Supriya Lifescience. Supriya Lifescience dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹1.00 per unit for 2026-March, a yield of 0.16%, compared with ₹1.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹1.00, ₹1.00 and ₹0.80 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹1.00 0.16%
2025-March ₹1.00 0.18%
2024-March ₹0.80 0.11%
2023-March ₹0.60 0.18%
2022-March ₹0.60 0.32%
2021-March ₹0.54 0.11%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Supriya Lifescience Stock Index Membership - Nifty & Sensex

See which indices include Supriya Lifescience stock. Check SUPRIYA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Supriya Lifescience Market Events Screener - Corporate Actions

Get Supriya Lifescience corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Supriya Lifescience stock events that may affect SUPRIYA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 6, 2026, with a record date of November 6, 2026.

It is followed by Annual General Meeting dated September 24, 2026 and Dividend dated September 4, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-06 2026-11-06 Quarterly Result Announcement NA 0.01%
2026-09-24 2026-09-24 Annual General Meeting NA 26.43%
2026-09-04 2026-09-04 Dividend ₹ 1.00 /share 8.03%
2026-08-13 2026-08-13 Quarterly Result Announcement NA -9.00%
2026-05-27 2026-05-27 Quarterly Result Announcement NA 8.24%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 0.36%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -6.66%
2025-09-24 2025-09-24 Annual General Meeting NA 11.37%
2025-09-04 2025-09-05 Dividend ₹ 1.00 /share -11.70%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -0.96%
2025-05-27 2025-05-27 Quarterly Result Announcement NA 5.82%
2025-01-24 2025-01-24 Quarterly Result Announcement NA 9.11%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -1.41%
2024-09-27 2024-09-27 Annual General Meeting NA -6.20%
2024-09-20 2024-09-21 Dividend ₹ 0.80 /share 74.84%

Supriya Lifescience Competitors Screener - Peer Stocks Comparison

Screen SUPRIYA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Supriya Lifescience Company Announcements - News & Reports Screener

Screen SUPRIYA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 15, 2026.

The next most recent announcements are dated November 9, 2026 and November 6, 2026.

Date Update Actions
2026-11-15 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-06 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-06 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-06 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-06 Announcement under Regulation 30 (LODR)-Change in Management -
2026-11-06 Financial Results For Quarter And Half Year Ended September 30 2026. -
2026-11-06 Board Meeting Outcome for Outcome Of Board Meeting For Quarter And Half Year Ended Ended September 30 2026. -
2026-11-02 Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015. -
2026-10-31 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-30 Board Meeting Intimation for Quarter And Half Year Ended September 30 2026 -
2026-10-19 Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015. -
2026-10-13 Announcement On ESG Ratings -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-08 Announcement Under Regulation 30 Of SEBI(LODR) Regulations 2015. -
2026-09-28 Closure of Trading Window -
2026-09-25 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-25 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-23 Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015. -
2026-09-20 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹614.80, within a 52-week range of ₹553.35 to ₹1,052.50. The P/E ratio is 28.30 and the P/B ratio is 4.03, with earnings per unit of ₹25.98. Market capitalisation stands at ₹4,995.16 Cr and the dividend yield is 0.16%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.